1 Combination of QTL and GWAS to uncover the role of phosphodiesterases in

- 2 ischemic heart disease
- Jun Xiao, M.D., Ph.D^{1,2}, Ziting Gao, M.D.³, Hongye Wei, M.D.³, Yajing Wei, M.D.³,
- 4 Ziyi Qiu, M.D.³, Wuqing Huang, M.D., Ph.D³
- ⁵ ¹ Department of Cardiovascular Surgery, Fujian Medical University Union Hospital,
- 6 Fuzhou, Fujian, China.
- ⁷ ² Fujian Provincial Clinical Research Center for Cardiovascular Diseases Heart Center of
- 8 Fujian Medical University, Fuzhou, Fujian, China.
- 9 ³ Department of Epidemiology and Health Statistics, School of Public Health, Fujian
- 10 Medical University, Fuzhou, Fujian, China.
- 11 ***Corresponding author:** Wuqing Huang
- 12 Fujian Medical University,
- 13 No 1, Xue Yuan Road, University Town, 350108
- 14 Fuzhou City, Fujian Province, China.
- 15 Email: <u>wuqing.huang@fjmu.edu.cn</u>
- 16 Telephone: +8617338896101
- 17 Short title: Phosphodiesterases and ischemic heart disease
- 18 Word count: abstract (246), main text (3403), figures (5)
- 19 Abbreviations: CHD, coronary heart disease; CI, confidence interval; CpG, Cytosine-
- 20 guanine dinucleotides; eQTLs, expression quantitative trait loci; GWAS, genome-wide
- 21 association study; HEIDI, heterogeneity in dependent instruments; mQTL, Methylation
- 22 quantitative trait loci; MI, myocardial infarction; OR, odds ratio; PDE,
- 23 phosphodiesterase; SNP, single-nucleotide polymorphism; SMR, summary-data-based
- 24 Mendelian Randomization.

25 Abstract

Background: Phosphodiesterases (PDEs) are regarded as important therapeutic targets for
multiple diseases, and the cardiovascular benefits of several PDE inhibitors have received
extensive interests.

29 **Objectives:** To explore the relationship between genetically-predicted PDEs and 30 ischemia heart disease via drug target Mendelian Randomization (MR) approach.

Methods: The expression of genes encoding PDEs was used to proxy the level of PDEs, and available quantitative trait loci of gene expression and DNA methylation (eQTLs and mQTLs) for each target gene were identified as the genetic instruments. Coronary heart disease (CHD) and myocardial infarction (MI) were the outcomes. Summary-data-based MR method was used to generate the estimates and two-step MR analysis was applied to investigate the mediation of metabolic traits.

37 **Results:** MR analyses identified two types of PDEs, PDE5 and PDE8, geneticallypredicted expression in blood of the encoded genes was significantly associated with the 38 risk of CHD (OR_{PDE5A}=1.22,95% CI=1.06-1.40; OR_{PDE8A}=1.26,95% CI=1.07-1.49) and 39 40 MI (OR_{PDE5A}=1.27,95% CI=1.09-1.48; OR_{PDE8A}=1.24,95% CI=1.04-1.48). Especially, the highest expression of PDE5A was observed in artery aorta, which was also positively 41 42 related to CHD (OR=1.17.95% CI=1.05-1.32) and MI (OR=1.15.95% CI=1.02-1.30). 43 Besides, the methylation level of 12 CpG sites showed a relation with CHD or MI via 44 affecting PDE5A expression. The observed association between PDE5A expression and 45 outcomes were partly mediated by blood pressure and LDL cholesterol, and the 46 association with MI were mostly mediated by CHD (Proportion-mediated: 78.84%). 47 Conclusions: This study provided genetic evidence about the protective role of PDE5 inhibition against ischemic heart disease, especially in preventing patients with CHD 48

49 from developing MI.

Keywords: phosphodiesterases, coronary heart disease, myocardial infarction, Mendelian
randomization.

52 Introduction

Phosphodiesterases (PDEs), a family of enzymes from PDE1 to PDE11, are well-known 53 54 to play a critical role in the regulation of intracellular signaling via hydrolyzing cyclic nucleotides cyclic adenosine monophosphate (cAMP) and/or cyclic guanosine 55 monophosphate (cGMP)(1). The cAMP and cGMP are the second messengers linking to 56 a series of physiological processes, thus PDEs are regarded as important therapeutic 57 targets for multiple diseases (2). Although the PDE families are structurally related, the 58 molecular diversity makes them functionally distinct (2). Some PDE inhibitors have 59 been widely used in clinical practice, and emerging evidence indicates that PDE 60 inhibitors have the potential to be developed or repurposed for a wide range of clinical 61 applications (2,3). 62

The cardiovascular benefits of PDE inhibitors have received extensive interests in 63 recent decades, for example, accumulating epidemiological studies suggested that PDE5 64 inhibitors could enhance contractile function for patients with heart failure, improve the 65 prognosis in patients with coronary heart disease, reduce ventricular arrhythmias, and so 66 67 on (4-16). Coronary heart disease (CHD) is the most common type of cardiovascular diseases, and myocardial infarction (MI) is a major cause of death worldwide. Since 68 69 1960s, cAMP and cGMP were found to inhibit platelet aggregation and a group of PDE inhibitors were considered as anti-platelet agents, for instance, dipyridamole (PDE3) 70 71 inhibitor) has been approved for secondary prevention of ischemic stroke (17). PDE inhibitors were also reported to ameliorate some established risk factors of coronary heart 72 73 disease, such as metabolic syndrome, a cluster of several metabolic disorders (18). Although these evidence have suggested the cardiovascular benefits of PDE inhibitors, 74 75 there is a paucity of studies comprehensively exploring the causal effect of PDE inhibitors on CHD or MI. 76

Randomized clinical trial (RCT) is recognized as the gold standard to confirm the causal effect, however, RCT is not always feasible due to the difficulty of implementation. Mendelian randomization (MR) is thus developed for causal inference by using genetic variants as instruments. Previous studies have applied drug-target MR method to explore the potential drug targets by using quantitative trait loci (QTLs) as

instruments, which are genetic variants associated with quantitative traits, such as gene
expression (eQTL), protein (pQTL), methylation (mQTL), et al(19,20).

Therefore, in this study, we aimed to investigate the role of PDEs on CHD and MI by using available eQTLs and mQTLs of genes encoding PDEs as instruments via MR approach and explore how the identified PDEs affect the outcome through metabolic traits.

88

89 Methods

90 Study design

The design of the study was summarized in Figure 1. In the primary analysis, we 91 comprehensively investigated the causal effect of the expression of genes encoding PDEs 92 93 on the risk of CHD or MI by using eQTLs from blood as instruments. For significant MR 94 associations, we further conducted a series of secondary analyses. Firstly, the observed significant associations were examined by using eQTLs in artery or heart tissues as 95 96 instruments. Secondly, it is known that DNA methylation plays an important role in 97 regulating gene expression, thus we further investigated the relationship between methylation level of related genes encoding significant PDEs and the outcomes by using 98 mQTLs in blood as instruments. Thirdly, two-step MR analysis was used to explore if 99 100 metabolic traits perform a mediating role between the identified PDEs and the outcomes, 101 including body mass index (BMI), blood pressure, blood lipids and blood glucose.

Summary-level data from publicly available genome-wide association studies (GWASs), expression and methylation quantitative trait loci (eQTLs and mQTLs) studies, were used in this study, all of which have been approved by the relevant institutional review boards with informed consents from participants. Details of data resources are presented in **Supplementary Table 1**.

107 Selection of genetic instruments

We used the expression of the encoded gene to proxy the level of each PDE, and eQTLs for related genes were used as instruments of gene expression. Given that data of eQTLs in blood are most comprehensive and top eQTLs are highly correlated between blood and other tissues, eQTLs in blood were used to generate genetic instruments to identified

112 significant PDEs in the primary analysis. For significant associations, we provided additional evidence by using eQTLs in disease-related organs (ie., artery and heart tissues) 113 114 as instruments. Summary-level data of eQTLs in blood and tissues were obtained from eQTLGen Consortium (N=31,684) and GTEx Consortium V8 (Artery Aorta: N=387; 115 Artery Tibial: N=372; Heart Atrial Appendage: N=584), respectively (21,22). And 116 117 common SNPs significantly associated with the expression and the methylation in blood for related genes were identified and used to generate instruments of the level of 118 methylation, summary data of mQTLs were selected from a meta-analysis of two cohorts 119 120 (N=1,980) (23). To reduce weak instrument bias, we only included cis-QTLs (i.e., QTLs within 1 Mb windows from the region of the encoded gene). Hence, common cis-eOTLs 121 or cis-mQTLs (minor allele frequency (MAF) >1%) significantly associated with the 122 expression or methylation of PDEs were identified, in which $p < 5.0 \square \times \square 10^{-8}$ was set as 123 the significant threshold to select cis-eQTLs or cis-mQTLs in blood and the threshold of 124 $p < 1.0 \square \times \square 10^{-5}$ was used to select cis-eOTLs in tissues due to the limited number of 125 available cis-eQTLs in tissues and the relatively small sample size of original studies. 126 127 The most significant cis-eQTL or cis-mQTL for each gene was finally selected as the 128 genetic instrument. The coefficient obtained from eQTL or mQTL study is equivalent to 129 1-SD change of the level of gene expression or DNA methylation for each additional 130 effect allele. The details of QTLs data are presented in **Supplementary Table 1.**

131 **Outcome sources**

The outcome is ischemic heart disease, including CHD and MI. The GWAS summary-132 level data for CHD (cases: N=60,801; controls: N=123,504) and MI (cases: N=43,676; 133 controls: N=128,199) were obtained from the CARDIoGRAMplusC4D Consortium with 134 135 meta-analyses of 48 GWASs, in which the study population was predominantly 136 individuals with European ancestry (24). Metabolic traits were considered as the potential mediators: summary data of GWAS for systolic and diastolic blood pressure was 137 obtained from the International Consortium of Blood Pressure; data for low-density 138 lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and 139 140 triglycerides (TG) obtained from the Global Lipids Genetics Consortium; data for body mass index obtained from the GIANT Consortium; data for fasting blood glucose 141

obtained from the MAGIC Consortium. The details of GWASs data are presented in Supplementary Table 1.

144 Statistical analyses

Effect estimates were generated by using summary-data-based MR (SMR) method, 145 146 which was recently developed to evaluate the association of quantitative trait and 147 outcome combining summary-level data from QTL and GWAS studies (25). F-statistic 148 was calculated to assess the strength of genetic instruments, an F-statistic of >10149 indicates a small role of weak instrument bias in the results (26). The heterogeneity in dependent instruments (HEIDI) test was applied to assess if linkage disequilibrium 150 151 played a role in the observed association of gene expression or methylation with outcome 152 of interest, in which p value <0.01 indicates that association may be due to linkage. One 153 SNP probably regulates the expression of more than one genes, resulting in the presence of horizontal pleiotropy. To evaluate the potential impact of horizontal pleiotropy, genes 154 155 near the instrumental variant (within a 1Mb window) were identified if the expression 156 was significantly associated with the variant. Then SMR analysis was conducted to examine if the instrumental variant affected the risk of outcomes via regulating the 157 expression of nearby genes. 158

Inverse-variance weighted mendelian randomization (IVW-MR) method was 159 applied to obtain the estimates of the causal associations between metabolic traits and the 160 161 outcome. To evaluate if the significant association between PDE and outcome was mediated by metabolic traits, we conducted a two-step MR study between PDE, 162 candidate mediators, and incident outcome. Two-step MR, also known as network MR, is 163 similar to the approach calculating the product of coefficients (27). We first calculated 164 165 two MR coefficients: the association between PDE and the mediator (beta1) and the association between the mediator and the outcome (beta2), then multiplied two 166 167 coefficients to estimate the indirect effect (beta1*beta2). The total effect was estimated 168 by MR coefficient of PDE on the outcome (beta0) and the direct effect was calculated by the difference between total effect and indirect effect (beta0-beta1*beta2). Proportion of 169 mediated effect was calculated by the formula of (beta1*beta2)/beta0. P-value of <0.05 170 171 was considered as statistical significance. To account for multiple testing correction,

172 Bonferroni correction was also used to adjust the thresholds of significance level, with a

strong evidence of P < 0.05 / (number of genes) and a suggestive evidence of 0.05 / (number of genes)

of genes) $\leq P < 0.05$. All analyses were conducted by using SMR software (version 1.03)

175 or R software (version 4.1.0).

176

177 **Results**

178 Genetic instrument selection

As shown in **Figure 1 and Supplementary Table 2**, a total of 7,737 SNPs significantly associated with the expression in blood of 17 genes encoding PDE1 to PDE9 were identified. While there is a lack of available cis-eQTLs identified for PDE10 and PDE11, thus these two PDEs were not included in the analyses. The most significant cis-eQTL for all 17 encoded genes had F statistics of >10, indicating a small role of weak instrument bias in our study. Approved or investigational drugs targeting PDEs are presented in **Supplementary Table 2**.

186 MR analysis between the expression of genes encoding PDEs in blood and outcomes

As shown in Figure 2 and Supplementary table 3, the most significant association with 187 188 the risk of both CHD and MI was found on PDE5A expression, in which a 1-SD increase of PDE5A expression was associated with increased risk of CHD with an OR of 1.22 (95% 189 CI=1.06-1.40, $P \square = \square 0.0046$) or MI with an OR of 1.27 (95% CI=1.09-1.48, 190 P = 0.0024). The observed association with MI kept significant after bonferroni 191 correction using a significance threshold of $P \square < \square 0.003$ (multiple testing for 17 genes) 192 193 and HEIDI test suggested a small role of linkage disequilibrium in the observed association (P_{CHD}=0.160; P_{MI}=0.375). Besides, MR analysis provided a suggestive 194 evidence for a positive association between PDE8A expression and the risk of CHD 195 196 (OR=1.26, 95% CI=1.07-1.49, P = 0.0047) and MI (OR=1.24, 95% CI=1.04-1.48, 9.0000)P = 0.0175, which tended to null after bonferroni correction and HEIDI test in MI 197 analysis showed the potential presence of linkage disequilibrium (P<0.01). As shown in 198 199 **Supplementary Table 5**, six genes were identified nearby the instrumental variant of 200 PDE5A expression in blood (rs10518336) and the expression of which were significantly

related to the instrumental variant. Among them, the expression of four genes were associated with the risk of outcomes, indicating that the horizontal pleiotropy may not be ruled out (**Supplementary Table 6**). No association was observed between the expression of gene nearby the instrumental variant of PDE8A expression in blood (rs67804993) and the outcomes (**Supplementary Table 6**).

MR analysis between the expression of PDE5A or PDE8A in artery or heart tissues and outcomes

208 As MR analyses found a strong evidence for the association between the expression of PDE5A or PDE8A and the risk of CHD and MI, we further examine the association of 209 210 PDE5A/PDE8A expression in relevant tissues with outcomes. Heart and artery are the 211 predominating organs in cardiovascular diseases. Supplementary Figure 1 and 2 display the tissue-specific expression of PDE5A and PDE8A from GTEx Portal. PDE5A 212 was expressed highest in artery aorta, followed by artery tibial, and the expression in 213 214 artery coronary ranked six place, indicating an important role of PDE5 in artery. While 215 PDE8A was expressed highest in nerve tibial, and the expression in artery tibial ranked 216 15 place.

217 There were 188, 13 and 9 cis-eQTLs identified to generate instruments for PDE5A expression in artery aorta, artery tibial and heart atrial appendage respectively, and 2 cis-218 eQTLs were identified as instruments for PDE8A expression in artery tibial (Figure 1). 219 220 As shown in **Figure 3 and Supplementary table 4**, the associations between PDE5A expression and the outcome were also found in artery aorta (OR_{CHD}=1.17, 95% CI=1.05-221 1.32, $P \square = \square 0.0066$; $OR_{MI} = 1.15$, 95% CI=1.02-1.30, $P \square = \square 0.0269$) and heart atrial 222 223 appendage (OR_{CHD}=1.20, 95% CI=1.02-1.41, $P \Box = \Box 0.0312$; OR_{MI}=1.18, 95% CI=0.99-224 1.40, $P \square = \square 0.0667$). The observed association with CHD passed the bonferroni correction test ($P \square < \square 0.013$, multiple testing for 4 genes) and the HEIDI test (P > 0.01). 225 226 No nearby genes were found to be significantly related to the instrumental variant of 227 PDE5A expression in artery aorta (rs1393966) (Supplementary table 5). No association was observed between the expression in heart atrial appendage of gene nearby the 228 229 instrumental variant of PDE5A expression (rs75098287) and the outcomes

(Supplementary Table 6). These results suggesting a small role of the horizontal
 pleiotropy in the observed associations.

232 MR analysis between the methylation of PDE5A or PDE8A in blood and outcomes

There were 1,185 and 310 cis-mQTLs in blood identified to generate instruments of DNA methylation in 14 CpG sites of PDE5A and 12 CpG sites of PDE8A, respectively (**Figure 1**). Among these CpG sites, the methylation level of 12 CpG sites of PDE5A and 7 CpG sites of PDE8A robustly associated with the expression of the corresponding gene had significant associations with the risk of CHD and MI in the same direction, indicating that methylation in these CpG sites may affect the outcomes via regulating gene expression(**Figure 4, Supplementary table 7 and 8**).

240 Two step MR analyses between PDE5A expression, metabolic traits and outcomes

As shown in **Supplementary table 9**, the expression of PDE5A but not PDE8A was 241 related to multiple metabolic traits, thus two step MR analyses were performed to explore 242 the causal relationship between PDE5A expression, metabolic traits and the risk of CHD 243 244 or MI. Figure 5 showed that the association between PDE5A expression and CHD or MI was partly mediated by diastolic blood pressure (Proportion-mediated _{CHD}=25.97%; 245 Proportion-mediated _{MI}=21.42%), systolic blood pressure (Proportion-mediated _{CHD} 246 =15.77%; Proportion-mediated $_{MI}$ =11.63%) and LDL-C (Proportion-mediated $_{CHD}$ 247 248 =15.35%; Proportion-mediated $_{MI}$ = 8.17%). The association between PDE5A expression and MI was mostly mediated by CHD (Proportion mediated=78.84%). No mediated role 249 250 of body mass index, blood glucose or other lipids was observed between PDE5A 251 expression and outcomes.

252 Discussion

To investigate the therapeutical potential of PDE inhibitors for ischemic heart disease and the underlying pathways, we explored the association of the expression of genes encoding PDEs (i.e., PDE1-PDE9) with the risk of CHD and MI in this MR study. Two types of PDEs, PDE5 and PDE8, were identified to have the potential to be repurposed for CHD or MI prevention in this study. Specifically, a strong evidence was observed for the positive association of PDE5A expression in blood and artery aorta (the tissue with

highest expression) with the risk of CHD and MI. We also identified 12 CpG sites, the methylation level of which was significantly related to the risk of CHD and MI via affecting the PDE5A expression. Mediation analysis suggested that PDE5 inhibition might reduce the incidence of ischemic heart disease partly through regulating blood pressure and LDL cholesterol. These findings provided genetic evidence that PDE5 inhibitors may be effective in the prevention of CHD and MI, especially in protecting against MI among patients with CHD.

PDE5, encoded by PDE5A gene, is an enzyme selectively hydrolyzing cGMP, 266 which is distributed across most tissues of human body. Thus, it is known that PDE5 267 inhibitors, including sildenafil, vardenafil and tadalafil, exert its therapeutic effect by 268 inhibiting cGMP degradation. PDE5 inhibitors were originally developed to treat angina 269 while failed in clinical trials, then repurposed and approved by FDA for treating erectile 270 dysfunction in 1998, pulmonary arterial hypertension in 2005 and benign prostatic 271 272 hyperplasia in 2011 (4-6). Given of the safety of PDE5 inhibitors and the involvement of cGMP in vast physiological processes, enormous interest has been raised to explore the 273 274 potential new functions of PDE5 inhibitors(6).

Growing preclinical studies have reported that PDE5 inhibitors play a protective role 275 276 against cardiovascular diseases, such as heart failure, MI, ischemia-induced ventricular 277 arrhythmias, myocardial hypertrophy and so on (4-6). Several clinical trials have 278 demonstrated the benefits of PDE5 inhibitors in patients with heart failure, while the effect on ischemic heart disease is still uncertain (28). A number of observational studies 279 280 have reported the protective effect of PDE5 inhibitors on ischemic heart disease (29-31). For example, a nationwide Danish cohort study including 71,710 men found that PDE5 281 282 inhibitors use was related to a decreased incidence of MI as compared to the general male population without receiving PDE5 inhibitors (RR=0.74; 95% CI=0.69-0.79), however 283 284 indication bias may play a role in the observed association (31). Another case-control study including type 2 diabetic men with silent coronary heart disease found that 285 286 treatment with PDE5 inhibitors and statins was negatively associated with the occurrence of major adverse cardiac events (HR=0.66, 95%CI=0.46-0.97), while in which the effect 287 of statins and PDE5 inhibitors cannot be distinguished and indication bias cannot be 288 289 eliminated as well(30). A recent real-world study based on Swedish nationwide registers

290 investigated the protective effect by comparing the survival between men treated with 291 PDE5 inhibitors and those treated with alprostadil in order to reduce the influence from 292 indication bias, since erectile dysfunction is the major indication of PDE5 inhibitors and alprostadil is another treatment for erectile dysfunction(29). This study included 18,542 293 294 men with stable coronary heart disease and found that men treated with PDE5 inhibitors 295 had a lower mortality as well as a reduced incidence of major adverse cardiac events, 296 including MI (HR= 0.81, 95%CI=0.70–0.93). Although indication bias can be reduced as much as possible by using active comparator, it is impossible to be completely avoided 297 298 and unknown confounders cannot be ruled out in observational studies. Besides, as these 299 drugs were mainly prescribed for men to treat erectile dysfunction in real world, it is 300 unlikely to assess the effect in general population. Our study observed consistent results 301 that increased expression of PDE5A was related to a higher risk of CHD and MI, which provided strong supportive evidence for findings from previous observational studies. 302 Besides, we found that the mediated proportion of CHD on the positive relation between 303 PDE5 and MI risk was as high as round 80%, indicating that PDE5 inhibition probably 304 305 contributed to preventing patients with CHD from MI. Furthermore, PDE5 has been 306 emerged as novel target for treating metabolic disorders, which are known risk factors of 307 ischemic heart disease (18). This study also observed a mediated effect of blood pressure 308 and LDL cholesterol between PDE5 inhibition and ischemic heart disease, which offered 309 some clues for the underlying mechanisms, calling for further studies.

PDE8 was also identified in this study, the inhibition of which was recently found to 310 311 be a potential novel therapeutic target of treating airway diseases and dementia (32,33). No studies reported the cardiovascular effect of PDE8. Although this MR study found 312 313 that the expression in blood of PDE8A was related to the risk of CHD and MI, the 314 association did not pass the bonferroni correction test. Besides, PDE8A was expressed less in cardiovascular organs and no relationship was observed between the PDE8A 315 expression in artery and the outcomes. Therefore, whether PDE8 inhibition really had a 316 317 cardiovascular benefit need to be further investigated.

This is the first MR study to comprehensively explore the causal effects of PDEs on ischemic heart disease. The use of QTLs as instruments to proxy drug exposure in MR study could overcome the shortcomings of observational studies, such as confounding

321 bias and reverse causation. Besides, several types of OTLs (eOTLs in blood, artery aorta 322 and heart, mQTLs in blood) have provided consistent evidence, indicating the robustness 323 of the protective effect of PDE5 inhibition on ischemic heart disease. Two-step MR analysis contributed to identifying the subgroup population that may benefit more from 324 325 PDE5 inhibitors use. However, there are several limitations. Firstly, this study used the expression of drug target genes to proxy drug exposure, which might not be equivalent to 326 327 clinical treatment because of a gap between drug targets and available agents, for example, there may be various effects across different types of PDE5 inhibitors. However, 328 these findings could provide additional evidence for previous observational studies 329 regarding the preventive effect of PDE5 inhibitors against ischemic heart disease. Hence, 330 RCTs are required to further investigate the efficacy of different PDE5 inhibitors. 331 Secondly, horizontal pleiotropy cannot be excluded when using eQTLs in blood as 332 instruments for PDE5A expression in primary analysis, while consistent associations 333 were observed using eQTLs in tissues or mQTLs in blood as instrument, suggesting the 334 robustness of the findings. Thirdly, false negative association of other PDEs cannot be 335 336 ruled out in drug target MR study as there may be unidentified eQTLs which play a more important role in gene expression than the identified top eQTL. Fourthly, this study was 337 338 conducted based on summary-level data, thus we were unable to explore the specific effect in subgroup population, such as in men and women. Fifthly, genetic data of this 339 340 study were mainly collected from population of European ancestry, leading to a limited generalization of these findings. 341

342 Conclusion

In conclusion, this drug-target MR study identified PDE5 that had the potential to be repurposed as novel target for CHD and MI prevention, especially in protecting against MI among patients with CHD, and the underlying mechanisms of the effect might be partly involved in regulating blood pressure and LDL cholesterol.

Acknowledgments: The data used for the analyses described in this manuscript were obtained from the eQTLGen Consortium, GTEx Portal, Global Lipids Genetics Consortium, International Consortium of Blood Pressure, GIANT Consortium, MAGIC Consortium and CARDIoGRAMplusC4D Consortium on 01/07/2023. We thank the patients and investigators who contributed to these studies.

353 Ethical statement: All publicly available genome-wide association studies (GWASs)

and quantitative trait loci (QTLs) studies used in this MR analyses were approved by the

relevant institutional review boards with informed consents from participants.

Funding Information: This work was supported by National Natural Science Foundation of China (82304213) and Start-up Fund for high-level talents of Fujian Medical University (XRCZX2021026) to Dr. Wuqing Huang. The funder had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

361 Author Contributors: All authors were responsible for the study concept and design.

WH obtained funding. JX did the statistical analysis. JX and WH drafted the manuscript,

and all authors revised it for important intellectual content.

364 **Competing interests:** The authors declare no conflict of interest.

365 **References**

366 1. Boswell-Smith V, Spina D, Page CP. Phosphodiesterase inhibitors. British journal of 367 pharmacology 2006;147 Suppl 1:S252-7. 368 2. Maurice DH, Ke H, Ahmad F, Wang Y, Chung J, Manganiello VC. Advances in targeting 369 cyclic nucleotide phosphodiesterases. Nature reviews Drug discovery 2014;13:290-314. 370 3. Huang W, Sundquist J, Sundquist K, Ji J. Use of Phosphodiesterase 5 Inhibitors Is 371 Associated With Lower Risk of Colorectal Cancer in Men With Benign Colorectal 372 Neoplasms. Gastroenterology 2019;157:672-681.e4. 373 4. Hutchings DC, Anderson SG, Caldwell JL, Trafford AW. Phosphodiesterase-5 inhibitors 374 and the heart: compound cardioprotection? Heart (British Cardiac Society) 375 2018;104:1244-1250. 376 5. Ravipati G, McClung JA, Aronow WS, Peterson SJ, Frishman WH. Type 5 377 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular 378 disease. Cardiology in review 2007;15:76-86. 379 Das A, Durrant D, Salloum FN, Xi L, Kukreja RC. PDE5 inhibitors as therapeutics for heart 6. 380 disease, diabetes and cancer. Pharmacology & therapeutics 2015;147:12-21. 7. 381 Hashimoto T, Kim GE, Tunin RS et al. Acute Enhancement of Cardiac Function by 382 Phosphodiesterase Type 1 Inhibition. Circulation 2018;138:1974-1987. 383 Nakano SJ, Miyamoto SD, Movsesian M, Nelson P, Stauffer BL, Sucharov CC. Age-related 8. 384 differences in phosphodiesterase activity and effects of chronic phosphodiesterase 385 inhibition in idiopathic dilated cardiomyopathy. Circulation Heart failure 2015;8:57-63. 386 9. Pagani ED, Buchholz RA, Silver PJ. Cardiovascular cyclic nucleotide phosphodiesterases 387 and their role in regulating cardiovascular function. Basic research in cardiology 1992;87 388 Suppl 1:73-86. 389 10. Kloner RA. Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for 390 the treatment of erectile dysfunction. Circulation 2004;110:3149-55. 391 Vinogradova TM, Lakatta EG. Dual Activation of Phosphodiesterase 3 and 4 Regulates 11. 392 Basal Cardiac Pacemaker Function and Beyond. International journal of molecular 393 sciences 2021;22. 394 12. Leroy J, Fischmeister R. Inhibit a Phosphodiesterase to Treat Heart Failure? Circulation 395 2018;138:2003-2006. 396 13. Roks AJM. Phosphodiesterase-1 in the cardiovascular system. Cellular signalling 397 2022;92:110251. 398 14. Bevan S, Porteous L, Sitzer M, Markus HS. Phosphodiesterase 4D gene, ischemic stroke, 399 and asymptomatic carotid atherosclerosis. Stroke 2005;36:949-53. 400 Lee DI, Zhu G, Sasaki T et al. Phosphodiesterase 9A controls nitric-oxide-independent 15. 401 cGMP and hypertrophic heart disease. Nature 2015;519:472-6. Chen S, Zhang Y, Lighthouse JK et al. A Novel Role of Cyclic Nucleotide 402 16. 403 Phosphodiesterase 10A in Pathological Cardiac Remodeling and Dysfunction. Circulation 404 2020;141:217-233. 405 17. Smolenski A. Novel roles of cAMP/cGMP-dependent signaling in platelets. Journal of 406 thrombosis and haemostasis : JTH 2012;10:167-76. Lugnier C, Meyer A, Talha S, Geny B. Cyclic nucleotide phosphodiesterases: New targets 407 18. 408 in the metabolic syndrome? Pharmacology & therapeutics 2020;208:107475. 409 19. Gaziano L, Giambartolomei C, Pereira AC et al. Actionable druggable genome-wide 410 Mendelian randomization identifies repurposing opportunities for COVID-19. Nat Med 411 2021;27:668-676.

20.	Huang W, Xiao J, Ji J, Chen L. Association of lipid-lowering drugs with COVID-19
	outcomes from a Mendelian randomization study. eLife 2021;10.
21.	Vosa U, Claringbould A, Westra HJ et al. Large-scale cis- and trans-eQTL analyses identify
	thousands of genetic loci and polygenic scores that regulate blood gene expression. Nat
	Genet 2021;53:1300-1310.
22.	Consortium GT. The GTEx Consortium atlas of genetic regulatory effects across human
	tissues. Science 2020;369:1318-1330.
23.	McRae AF, Marioni RE, Shah S et al. Identification of 55,000 Replicated DNA Methylation
	QTL. Sci Rep 2018;8:17605.
24.	Nikpay M, Goel A, Won HH et al. A comprehensive 1,000 Genomes-based genome-wide
	association meta-analysis of coronary artery disease. Nat Genet 2015;47:1121-1130.
25.	Zhu Z, Zhang F, Hu H et al. Integration of summary data from GWAS and eQTL studies
	predicts complex trait gene targets. Nat Genet 2016;48:481-7.
26.	Burgess S, Thompson SG. Avoiding bias from weak instruments in Mendelian
	randomization studies. Int J Epidemiol 2011;40:755-64.
27.	Carter AR, Sanderson E, Hammerton G et al. Mendelian randomisation for mediation
	analysis: current methods and challenges for implementation. Eur J Epidemiol
	2021;36:465-478.
28.	Nadur NF, de Azevedo LL, Caruso L, Graebin CS, Lacerda RB, Kümmerle AE. The long and
	winding road of designing phosphodiesterase inhibitors for the treatment of heart
	failure. European journal of medicinal chemistry 2021;212:113123.
29.	Andersson DP, Landucci L, Lagerros YT et al. Association of Phosphodiesterase-5
	Inhibitors Versus Alprostadil With Survival in Men With Coronary Artery Disease. Journal
	of the American College of Cardiology 2021;77:1535-1550.
30.	Gazzaruso C, Solerte SB, Pujia A et al. Erectile dysfunction as a predictor of
	cardiovascular events and death in diabetic patients with angiographically proven
	asymptomatic coronary artery disease: a potential protective role for statins and 5-
	phosphodiesterase inhibitors. Journal of the American College of Cardiology
	2008;51:2040-4.
31.	Vestergaard N, Søgaard P, Torp-Pedersen C, Aasbjerg K. Relationship between
	treatment of erectile dysfunction and future risk of cardiovascular disease: A nationwide
	cohort study. European journal of preventive cardiology 2017;24:1498-1505.
32.	Johnstone TB, Smith KH, Koziol-White CJ et al. PDE8 Is Expressed in Human Airway
	Smooth Muscle and Selectively Regulates cAMP Signaling by beta(2)-Adrenergic
	Receptors and Adenylyl Cyclase 6. Am J Respir Cell Mol Biol 2018;58:530-541.
33.	Wu XN, Zhou Q, Huang YD et al. Structure-based discovery of orally efficient inhibitors
	via unique interactions with H-pocket of PDE8 for the treatment of vascular dementia.
	Acta Pharm Sin B 2022;12:3103-3112.
	 20. 21. 22. 23. 24. 25. 26. 27. 28. 29. 30. 31. 32. 33.

Figure legends:

Figure 1. Flowchart of the study.

Figure 2. Association between the expression of PDEs in blood and coronary heart disease or myocardial infarction. (A) Coronary heart disease; (B) Myocardial infarction. * Shown in ascending order of p value.

Figure 3. Association between the expression of PDE5A or PDE8A in artery or heart tissue and coronary heart disease or myocardial infarction.

Figure 4. Association between the methylation of PDE5A or PDE8A and the gene expression in blood, coronary heart disease or myocardial infarction. (A) PDE5A; (B) PDE8A.

Figure 5. Two-step mendelian randomization between PDE5A expression, metabolic traits and coronary heart disease or myocardial infarction. (A) Coronary heart disease; (B) Myocardial infarction. * Percentage in plots indicates the proportion of mediated effect. The asterisk in plots indicates statistical significance (P<0.05).

Supplementary files:

Supplementary Table 1. Information of eQTL and GWAS summary data.

Supplementary Table 2. Information of PDE family.

Supplementary Table 3. SMR association between the expression of genes encoding PDEs in blood and coronary heart disease or myocardial infarction.

Supplementary Table 4. SMR association between the expression of PDE5A or PDE8A in artery or heart tissue and coronary heart disease or myocardial infarction.

Supplementary Table 5. The eQTL association between top SNP of PDE5A or PDE8A with the expression of other nearby genes.

Supplementary Table 6. SMR association between the expression of genes adjacent to PDE5A or PDE8A and coronary heart disease or myocardial infarction.

Supplementary Table 7. SMR association between the methylation of PDE5A and the PDE5A expression in blood, coronary heart disease or myocardial infarction.

Supplementary Table 8. SMR association between the methylation of PDE8A and the PDE8A expression in blood, coronary heart disease or myocardial infarction.

Supplementary Table 9. SMR association between the expression of PDE5A or PDE8A in blood and metabolic traits.

Supplementary Table 10. IVW-MR association between metabolic traits and coronary heart disease or myocardial infarction.

Supplementary Table 11. Two-step mendelian randomization between PDE5A expression in blood, metabolic traits and coronary heart disease or myocardial infarction.

Supplementary Figure 1. Tissue gene expression for PDE5A from GTEx Portal.

Supplementary Figure 2. Tissue gene expression for PDE8A from GTEx Portal.



Exposure	Instrumental variant	t.	OR (95% CI)	P
PDE5A	rs10518336	╎┝╼╋╋╼╼╡	1.22 (1.06-1.40)	4.56E-03
PDE8A	rs62022525	·∎	1.26 (1.07-1.49)	4.66E-03
PDE6H	rs61041959	ik ≣ -1	1.08 (0.99-1.18)	9.12E-02
PDE3B	rs12270702	v <mark>, ∎</mark>	1.13 (0.97-1.31)	1.20E-01
PDE6G	rs57135500	r-¦∎•	1.09 (0.93-1.28)	2.92E-01
PDE2A	rs11235547		0.91 (0.76-1.10)	3.41E-01
PDE4B	rs12731764	⊢∎∔→	0.91 (0.75-1.11)	3.49E-01
PDE4D	rs9291685	⊢₩	1.04 (0.95-1.13)	4.26E-01
PDE8B	rs163037	H ali h	0.98 (0.91-1.05)	5.25E-01
PDE9A	rs2839581	.	1.01 (0.98-1.04)	5.78E-01
PDE6D	rs838446	⊢∎	0.98 (0.87-1.10)	6.95E-01
PDE1B	rs1874308	.	0.99 (0.94-1.04)	7.20E-01
PDE6B	rs4463020	H	0.99 (0.89-1.10)	8.17E-01
PDE4A	rs77376335	, ⊢ ∰,	0.99 (0.84-1.16)	8.71E-01
PDE7B	rs9389345	₽ 1	0.99 (0.76-1.28)	9.17E-01
PDE6C	rs11187583	i	1.02 (0.72-1.43)	9.19E-01
PDE7A	rs62506599		1.00 (0.83-1.19)	9.58E-01
		0.6 0.8 1 1.2 1.4 1	.6	

Exposure	Instrumental variant		OR (95% CI)	P
PDE5A	rs10518336	¦ ⊨ 	1.27 (1.09-1.48)	2.44E-03
PDE8A	rs62022525	⊢	1.24 (1.04-1.48)	1.75E-02
PDE6D	rs838446	H∎∔	0.91 (0.81-1.04)	1.63E-01
PDE3B	rs12270702	⊢ † ∎ 4	1.11 (0.94-1.31)	2.19E-01
PDE6G	rs57135500	⊢÷∎	1.12 (0.93-1.35)	2.36E-01
PDE4A	rs77376335	⊢-∎¦-	0.91 (0.76-1.09)	3.23E-01
PDE6H	rs61041959	F i⊞ -1	1.05 (0.95-1.15)	3.36E-01
PDE2A	rs11235547	┝╌╋┼┙	0.91 (0.75-1.12)	3.85E-01
PDE9A	rs2839581	P	1.01 (0.98-1.05)	4.49E-01
PDE4B	rs12731764	┝╌╴╋┊╌┥	0.93 (0.76-1.15)	5.29E-01
PDE7A	rs62506599	⊢−₽	1.04 (0.86-1.27)	6.61E-01
PDE4D	rs9291685	⊢∰⊒⊣	1.02 (0.93-1.12)	7.03E-01
PDE1B	rs1874308	.	0.99 (0.94-1.05)	8.51E-01
PDE8B	rs163037	⊢ ∰ -i	1.00 (0.92-1.08)	9.08E-01
PDE7B	rs9389345	⊢ 	0.98 (0.74-1.31)	9.12E-01
PDE6C	rs11187583	⊢∎	0.98 (0.67-1.43)	9.24E-01
PDE6B	rs4463020		0.99 (0.88-1.12)	9.26E-01
	0	.6 0.8 1 1.2 1.4 1	.6	

Outcome	Exposure	Tissue	Instrumental varian	nt	OR (95% CI)	P
Coronary heart disease						
	PDE5A	Artery Aorta	rs1393966	⊢ ≣ 4	1.17 (1.05-1.32)	6.60E-03
		Heart Atrial Appendage	rs75098287	<u> </u> ⊢-∎+	1.20 (1.02-1.41)	3.12E-02
		Artery Tibial	rs111837430	⊧¦∎	1.15 (0.96-1.38)	1.21E-01
	PDE8A	Artery Tibial	rs112008279		1.20 (1.00-1.45)	5.23E-02
Myocardial infarction						
	PDE5A	Artery Aorta	rs1393966	i⊢ ≣ 1	1.15 (1.02-1.30)	2.69E-02
		Heart Atrial Appendage	rs75098287	⊨ ∎1	1.18 (0.99-1.40)	6.67E-02
		Artery Tibial	rs111837430	r ¦-∎ 1	1.14 (0.94-1.39)	1.70E-01
	PDE8A	Artery Tibial	rs112008279		1.14 (0.93-1.39)	2.13E-01
				0.8 1 1.2 1.4 1	1 .6	

Exposure Instrumental variant Outcome

OR (95% CI) P

cg18483704	rs66887589			1					
		PDE5A expression			L.	→ 1.84 (1.47-2.30)	1.15E-07		
		Coronary heart disease		i ⊨ – – – – – – – – – – – – – – – – – – –		1.16 (1.05-1.30)	5.81E-03		
		Myocardial infarction		H 🖬		1.19 (1.05-1.34)	5.50E-03	Exposure	Inst
cg01778622	rs79026312							cg10587940	rs12
U		PDE5A expression		F F		→ 1.57 (1.31-1.88)	8.73E-07	5	
		Coronary heart disease		· · · · · · · · · · · · · · · · · · ·		1.20 (1.06-1.36)	3 27E-03		
		Mvocardial infarction		· · · · · · · · · · · · · · · · · · ·		1.20 (1.06-1.37)	578E-03		
ca02673944	rs11098493	,						cq09425164	rs34
		PDE5A expression				\rightarrow 1 44 (1 25-1 66)	4 07E-07	-9	
		Coronary heart disease				1 17 (1 05-1 29)	3.79E-03		
		Myocardial infarction				1 17 (1.05-1.20)	6.02E-03		
ca15446520	rc13123280	Myocardiarmarciion				1.17 (1.00-1.01)	0.022-00	cg250/1682	re11
cg13440320	1313123203	DDE5A ovproceion			_	1 34 (1 17 1 54)	3 30E 05	Cg20341002	131
		Coronary boart disease			_	1.54 (1.17-1.54)	1.09E 02		
		Musserdial infertion				1.10 (1.05-1.29)	7.055.02		
	40007070	wyocardial infarction		-	-1	1.19 (1.05-1.35)	7.25E-03		
Cg07154408	1510027976				· .	4 00 (4 47 4 54)	0.045.00	cg1/133/34	ISIC
medRxiv pre	print doi: https://doi.org/10.1101/2	PDE5A expression 023.09.24.23296052; this version post	ed September 25, 2023. The copyrigh	tholder for this		1.33 (1.17-1.51)	8.61E-06		
preprint (which	All rigi	is the authornunder aviornas granted hts reserved. No reuse allowed without	permission.			1.17 (1.04-1.31)	6.32E-03		
		Myocardial infarction				1.20 (1.06-1.36)	4.21E-03		
cg09350414	rs28581362			_				cg19183879	rs92
		PDE5A expression				1.29 (1.18-1.41)	3.59E-08		
		Coronary heart disease				1.13 (1.04-1.22)	3.90E-03		
		Myocardial infarction				1.15 (1.05-1.25)	2.95E-03		
cg05550861	rs28581362							cg11038343	rs80
		PDE5A expression		<u>⊢</u> ∎1		1.21 (1.14-1.28)	5.45E-10		
		Coronary heart disease		<u> </u> ⊢− ∎−−−4		1.09 (1.03-1.16)	2.94E-03		
		Myocardial infarction		⊢−∎−− 1		1.11 (1.04-1.18)	2.15E-03		
cg10183150	rs13139045							cg02903680	rs71
		PDE5A expression				1.17 (1.11-1.23)	4.26E-10		
		Coronary heart disease				1.07 (1.02-1.13)	2.92E-03		
		Myocardial infarction		⊢_∎_ i		1.07 (1.02-1.13)	7.23E-03		
cg14736911	rs34624042							cg02913089	rs89
		PDE5A expression		⊢∎⊣		1.11 (1.08-1.14)	1.55E-13		
		Coronary heart disease	F	₩ -1		0.99 (0.96-1.02)	5.83E-01		
		Myocardial infarction	ι · · · ·	₩		0.99 (0.96-1.02)	5.61E-01		
cg24657788	rs61015834							cg15029032	rs55
		PDE5A expression		⊢≣ -		1.10 (1.06-1.13)	5.42E-10		
		Coronary heart disease	+			0.99 (0.96-1.02)	5.45E-01		
		Myocardial infarction		H B -1		1.01 (0.98-1.05)	3.82E-01		
cg08957091	rs11737400							cg25846076	rs28
0.0000000000000000000000000000000000000		PDE5A expression	⊢ <mark>∎</mark> -1			0.79 (0.76-0.82)	1.52E-28		
		Coronary heart disease	⊢≣ -	-		0.95 (0.92-0.98)	4.42E-03		
		Myocardial infarction	⊢ ∎-	-		0.94 (0.90-0.98)	1.81E-03		
cq21123740	rs12505735							cq19686637	rs72
		PDE5A expression	⊢∎ 1			0.83 (0.79-0.87)	4.64E-12		
		Coronary heart disease	L-B			0.92 (0.88-0.97)	1.19E-03		
		Myocardial infarction	⊢ ∎	-		0.93 (0.88-0.98)	8.96E-03		
cg26975461	rs10213342					,		cg23334467	rs58
		PDE5A expression	H a t			0.90 (0.87-0.92)	3.73E-19	3	
		Coronary heart disease	F	H		0.96 (0.94-0.99)	3.33E-03		
		Myocardial infarction	H	H		0.96 (0.93-0.99)	3.14E-03		
cg16056087	rs6832410								
59.0000001		PDF5A expression	⊢ —–			0.90 (0.88-0.93)	2.95E-11		
		Coronary heart disease		4		0.95 (0.92-0.98)	1.53E-03		
		Myocardial infarction		4		0.94 (0.91.0.98)	124E-03		
		My ocur and marchon			Î.		1.272-00		
		(0.6 0.8	1 12	1.4	1.6			

t) J.c	50E-03	Exposure	Instrumental variant	Outcome			OR (95% CI)	Ρ
		cg10587940	rs12905036		i			
3) 8.7	73E-07			PDE8A expression	1	i — ≣ — (1.21 (1.11-1.32)	7.71
3) 3.2	27E-03			Coronary heart disease	1	⊢	1.17 (1.07-1.28)	8.84
5.7	78E-03			Myocardial infarction		F	1.19 (1.08-1.32)	7.88
,		ca09425164	rs34731527	,	i		,	
s) 4 (07E-07	-9		PDE8A expression	Ì	⊢∎⊣	1 20 (1 16-1 24)	1 94
3) 37	79E-03			Coronary heart disease		- -	1.06 (1.02-1.10)	9.23
0.0	12E-03			Myocardial infarction			1.06 (1.02-1.10)	1 18
1) 0.0	JZL-05	ca250/1682	rc11621171	Myocardiarmarciion		- 12	1.00 (1.00-1.11)	1.10
1) 23		Cy25941002	1511031171				1 14 (1 00 1 10)	2 42
+) 0.0	DOE-00			Coronany baset disease		A 🖬 A	1.14 (1.09-1.19)	2.43
) I.U	JOE-02			Coronary near disease			0.98 (0.93-1.03)	3.00
o) 7.2	25E-03	17100701	1500.405	Myocardial infarction		1	0.98 (0.92-1.04)	4.94
		cg17133734	rs1533125					
1) 8.6	61E-06			PDE8A expression		⊢∎ →	1.11 (1.07-1.16)	4.82
1) 6.3	32E-03			Coronary heart disease	H		1.06 (1.01-1.11)	2.95
6) 4.2	21E-03			Myocardial infarction	ŀ		1.07 (1.02-1.13)	1.24
		cg19183879	rs925412		1			
1) 3.5	59E-08			PDE8A expression	1	H II -I	1.07 (1.05-1.10)	1.14
2) 3.9	90E-03			Coronary heart disease	H	∎⊣	1.04 (1.00-1.07)	2.80
5) 2.9	95E-03			Myocardial infarction	Į.	-	1.05 (1.01-1.09)	8.41
		cg11038343	rs8040292		1			
3) 5.4	45E-10			PDE8A expression		ਮ≣ ⊣	1.07 (1.05-1.10)	6.74
5) 2.9	94E-03			Coronary heart disease	-	H	1.03 (1.00-1.06)	6.14
3) 21	15E-03			Myocardial infarction	H	H	1 03 (1 00-1 07)	4 68
,	.02.00	ca02903680	rs7173332	infocardia marciron	1		1.00 (1.00 1.01)	1.00
3) 4 2	26E-10	cg02500000	131 11 0002				0.66 (0.58.0.75)	6 28
3) 20	D2E 03			Coronany heart disease			0.88 (0.81 0.96)	2.76
2) 7 2	02E-03			Myocardial infarction			0.88 (0.80 0.06)	4.06
) 1.Z	232-03	02012090	rc906264	Myocardiarmarciton			0.88 (0.80-0.90)	4.90
	EEE 40	Cy02913069	15090304				0.00 (0.50.0.75)	4 201
+) 1.5 >> 5.6	DDE-13						0.66 (0.58-0.75)	1.29
2) 5.8	33E-01			Coronary neart disease			0.90 (0.83-0.98)	1.08
2) 5.6	51E-01			Myocardial Infarction			0.89 (0.81-0.98)	1.3/1
120	-	cg15029032	rs55649640					
3) 5.4	42E-10			PDE8A expression			0.77 (0.68-0.87)	3.41
2) 5.4	45E-01			Coronary heart disease		-	0.96 (0.88-1.06)	4.62
5) 3.8	32E-01			Myocardial infarction	r		0.99 (0.88-1.10)	8.17
		cg25846076	rs289384					
2) 1.5	52E-28			PDE8A expression	⊢∎		0.81 (0.74-0.88)	1.93
3) 4.4	42E-03			Coronary heart disease	⊢ ∎ †	1	0.97 (0.90-1.04)	4.13
3) 1.8	81E-03			Myocardial infarction	⊢ ■ ┼	6 2	0.95 (0.88-1.04)	2.67
		cg19686637	rs72759100					
() 4.6	64E-12			PDE8A expression	⊢∎→		0.85 (0.80-0.90)	1.43
7) 1.1	19E-03			Coronary heart disease	H III	— 1	1.02 (0.96-1.08)	5.61
8) 8.9	96E-03			Myocardial infarction			1.02 (0.96-1.09)	4.91
		cg23334467	rs58943832				and an	
2) 37	73E-19			PDE8A expression	⊨∎-i		0 86 (0 81-0 91)	3.70
3) 33	33E-03			Coronary heart disease			0.97 (0.92-1.02)	2 26
1 0.0	01.00			Myocardial infarction			0.06 (0.01 1.02)	1.00

